Document is current
Any future updates will be listed below
-
Authors
Wang, Bruce https://orcid.org/0000-0003-4930-0998
Lin, Aaron E. https://orcid.org/0000-0001-7400-4125
Yuan, Jiayi https://orcid.org/0009-0007-0121-4990
Novak, Katherine E. https://orcid.org/0009-0001-3564-9841
Koch, Matthias D. https://orcid.org/0000-0003-4408-9900
Wingreen, Ned S. https://orcid.org/0000-0001-7384-2821
Adamson, Britt https://orcid.org/0000-0002-9451-5819
Gitai, Zemer https://orcid.org/0000-0002-3280-6178
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (DP1AI124669, GM082938, T32HG003284)
NSF | BIO | Division of Molecular and Cellular Biosciences (MCB-2033020)
NSF | Directorate for Mathematical & Physical Sciences | Division of Physics (PHY-1734030)
Damon Runyon Cancer Research Foundation (DRG-2432-21)
CSC | Distinguished International Students Scholarship
Deutsche Forschungsgemeinschaft (Ko5239/1-1)
- License Information
-
More Information
Article History
Received: 28 November 2022
Accepted: 31 July 2023
First Online: 31 August 2023
Competing interests
: B.A. is an advisory board member, with options, for Arbor Biotechnologies and Tessera Therapeutics and holds equity in Celsius Therapeutics. Z.G. is the founder of ArrePath. The remaining authors declare no competing interests.
